Summary
Twelve psychotic patients received a mean dose of 3.3 mg/day of clonidine. In four clonidine was the only treatment and in the remaining eight clonidine was superadded to a neuroleptic regimen after symptomatology was stable. Clonidine caused reduction of scores for both productive psychotic symptoms and anxiety. Negative symptoms were unaffected. These findings are discussed with respect to the small magnitude of the effects, questions as to specificity of the effects and methodologic limitations of this pilot study.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Abrams R, Taylor MA (1978) A rating scale for emotional blunting. Am J Psychiatry 135: 226–229
Adler LE, Bell J, Kirch D, Friedrich E, Freedman R (1982) Psychosis associated with clonidine withdrawal. Am J Psychiatry 139: 110–112
Adler LA, Angrist B, Peselow E, Corwin J, Maslansky R, Rotrosen J (1986) A controlled assessment of propranolol in the treatment of neuroleptic induced akathisia. Br J Psychiatry 149: 42–45
Adler LA, Angrist B, Peselow E, Reitano J, Rotrosen J (1987) Clonidine in neurolepticinduced akathisia. Am J Psychiatry 144: 230–235
Antelman SM, Caggiula AR (1977) Norepinepherine-dopamine interactions and behavior. Science 195: 646–653
Engel JA, Johannessen K, Liljequist S, Goldstein M (1986) Activation of α2-adrenoreceptors enhanced haloperidol-induced suppression of operant behavior. J Neural Transm 66: 107–120
Freedman R, Bell J, Kirch D (1980) Clonidine therapy for coexisting psychosis and tardive dyskinesia. Am J Psychiatry 137: 629–630
Gold MS, Pottash AC, Annitto W, Extein I, Kleber HD (1981) Lofexidine a clonidine analogue effective in opiate withdrawal. Lancet 1: 992–993
Freedman R, Kirch D, Bell J, Adler LF, Pecevich M, Pachtman E, Denver P (1982) Clonidine treatment of schizophrenia. Double blend to comparison to placebo and neuroleptic drugs. Acta Psychiat Scand 65: 35–45
Guy W (1976) ECDEU Assessment manual for psychopathology. U.S. Department of Health Education and Welfare, Washington, D.C., DHEW publication No. (ADM) 76-338, pp 158–169
Hamilton M (1959) The assessment of anxiety states by rating. Br J.Med.Psychol 32: 50–55
Hornykiewicz O (1982) Brain catecholamines in schizophrenia — a good case for noradrenaline. Nature 299: 434–436
Jimerson DC, Post RM, Stoddard FJ, Gillin JC, Bunney WE Jr (1980) Preliminary trial of the noradrenergic agonist clonidine in psychiatric patients. Biol Psychiatry 15: 45–54
Jouvent R, Lecrubier Y, Puech AJ, Simon P, Widlockler D (1980) Antimanic effect of clonidine. Am J Psychiatry 137: 1275–1276
Langer SZ (1977) Presynaptic receptors and their role in the regulation of transmitter release. Br J Pharmacol 60: 481–497
Simpson GM, Kunz-Bartholini D, Watts TPS (1967) A preliminary evaluation of the sedative effects of catapress, a new-antihypertensive agent in chronic schizophrenic patients. J Clin Pharmacol 7: 221–225
van Kammn DP, Antelman S (1984) Impaired noradrenergic transmission in scizophrenia? Life Sci 34: 1403–1413
Van Putten T (1974) Why do schizophrenic patients refuse to take their drugs? Arch Gen Psychiatry 31: 67–72
Washton AM, Resnick RB, Perzel JF Jr, Garwood J (1981) Lofexidine, a clonidine analogue effective opiate withdrawal. Lancet 1: 991–992
Zubenko GS, Cohen BM, Lipinski JF, Jones JM (1984) Clonidine in the treatment of mania and mixed bipolar disorder, Am J Psychiatry 141: 1617–1618
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Angrist, B., Smith, M., Adler, L. et al. Preliminary studies of clonidine in psychotic patients. J. Neural Transmission 71, 115–121 (1988). https://doi.org/10.1007/BF01245253
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01245253